PARP inhibition is a targeted strategy to induce synthetic lethality in tumors, such as HGSOC, with BRCA1/2 mutations or homologous recombination deficiency (HRD).36, 37. This evidence concerns the gene BRCA1 and hypoparathyroidism-retardation-dysmorphism syndrome.